IKCC Kidney Cancer

Learn more on #WorldHealthDay: ikcc.org/the-discern-pr… (4/4)

IKCC has a unique role in the DISCERN project to ensure that patients and caregivers are represented throughout, and results are relevant to the patient community, and that findings are communicated in plain language. (3/4)

DISCERN is a five-year project of the European Commission Cancer Mission to understand the causes of renal (kidney), pancreatic, and colorectal cancer in Europe and to help explain the geographical distribution of these cancer types, (1/4)

which is a four-year project that aims to enhance cancer care through data-driven decision support systems. The project is funded by the European Union. On #WorldHealthDay, learn more about this project: ikcc.org/research-initi… (2/2)

We’re proud to be a member of the COMFORT project (Computational Models FOR patienT stratification in urologic cancers – Creating robust and trustworthy multimodal AI for health care), (1/2)

With funding from the European Union’s Horizon Europe research and innovation programme, the project is a phase III multi-centre study of first-line treatment for metastatic #KidneyCancer. Learn more: ikcc.org/research-initi… #WorldHealthDay (2/2)

We’re proud to be a full member of the Management Board of the CARE1 Pragmatic Clinical Trial. (1/2)

Notably, Ono Pharmaceutical and avec are collaborating on a shared decision-making project specifically focused on kidney cancer (Renal Cell Carcinoma). (2/2)

Our Chair, Dr Eric Jonasch, was in Japan to meet with the Japanese Society of Medical Oncology, the kidney cancer patient organisation avec, and Ono Pharmaceutical. (1/2)

As we mark the end of #ECCAM2026, we are proud to spotlight the DISCERN project, an EU-funded initiative in which DiCE, alongside our partners @P_C_E_, @IKCCorg, and Instytut Medycyny Pracy w Łodzi, ensures that the patient perspective remains central to the research.

Rare kidney cancers require focused research and strong partnerships. The tRCC Project is working to accelerate discovery for translocation renal cell carcinoma (tRCC) by bringing together researchers and patients to better understand this rare subtype. If you or a loved one has been diagnosed with tRCC in the U.S. or Canada, participating can help advance knowledge and future treatment options. Learn more at trccproject.org #AcceleratingCures #KidneyCancerAwarenessMonth #BetterTogether

All presentations at #KCRS26 are in person, with accepted presenters receiving full support to attend. Join the #KidneyCancer research community in Boston, July 23–24! Submit your abstract by May 4, 2026: kcrs.kidneycan.org/call-for-abstr… #AcceleratingCures

The new ECO report highlights these challenges and the need for coordinated action. Read more: europeancancer.org/resources/news… @EuropeanCancer (2/2)

Back in November, IKCC participated in the European Cancer Organisation Summit. Recognising the barriers that patients face across the cancer care pathway is key to advancing the priorities of the cancer community. (1/2)

Scientific progress doesn’t happen in isolation. Research conferences like the Kidney Cancer Research Summit bring together scientists, clinicians, industry leaders, and patient advocates to share discoveries, exchange ideas, and accelerate progress in #KidneyCancer research. These collaborations help turn new insights from the lab into better treatments and care for patients. #AcceleratingCures #KidneyCancerAwarenessMonth #KnowledgeIsPower

Read the 2025 GPS Highlights Report at: ikcc.org/wp-content/upl… #KidneyCancer (3/3)

However, there is still room for improvement. Those who reported less than ‘Satisfied’ still represent approximately 1 in 5 clinical trial participants. (2/3)

When asked about their level of satisfaction with their participation in a clinical trial, overall, 2025 Global Patient Survey respondents said they were more satisfied than in the previous survey. (1/3)

Scientists are exploring new tools and technologies, from biomarkers that could guide personalized treatment, to AI-driven tools that help detect and analyze tumors, to combination therapies designed to improve treatment outcomes. Each discovery helps researchers better understand the disease and develop more effective strategies for treating it. Progress takes collaboration, investment, and time, but each step forward brings us closer to more precise, personalized care for people living with #KidneyCancer. #AcceleratingCures #KidneyCancerAwarenessMonth #KnowledgeIsPower